Oral · GLP-1 agonist
Orforglipron
49 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
49
Ongoing
17
Recruiting
6
Completed
32
Sites
1,691
Countries
43
Endpoints
476
Composite endpoints
8
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
21
Phase 2
2
Phase 3
25
Phase 4
1
Trials by status
Not yet recruiting
3
Recruiting
6
Active, not recruiting
8
Completed
32
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
165
Weight & body composition
108
Glycemic / diabetes
81
Cardiometabolic biomarkers
66
Patient-reported / QoL
25
Other clinical outcomes
15
Other (unclassified)
9
Cardiovascular outcomes
4
Heart failure
2
Renal / kidney
1
Top 20 metrics across this asset's endpoints
AUC₀-∞Safety/PK
40
CmaxSafety/PK
34
Body weight, % changeWeight
25
HbA1c, changeGlycemic
21
Fasting glucose, changeGlycemic
18
Body weight, absolute change (kg)Weight
18
Systolic BP, changeBiomarker
18
Waist circumference, changeWeight
15
≥5% weight-loss respondersWeight
13
Triglycerides, changeBiomarker
12
BMI, changeWeight
11
Non-HDL cholesterol, changeBiomarker
10
HbA1c <7.0% achievementGlycemic
10
HbA1c <6.5% achievementGlycemic
9
≥10% weight-loss respondersWeight
9
hs-CRP, changeBiomarker
7
TmaxSafety/PK
7
Total cholesterol, changeBiomarker
6
SF-36 totalPRO/QoL
5
≥15% weight-loss respondersWeight
5
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
49 of 49
Showing 1-25 of 49 trials